Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.75 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2369806 | 0.98 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL2369290 | 0.98 | TBXAS1 (0.79) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL7276913 | 0.98 | TBXAS1 (0.72) | TBXAS1 | |
| SCHEMBL3173441 | 0.98 | TBXAS1 (0.79) | TBXAS1 | |
| Bromide SCHEMBL18941395 | 0.98 | TBXAS1 (0.72) | TBXAS1HMOX1PRKCI | |
| SCHEMBL7276173 | 0.98 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL5988937 | 0.98 | TBXAS1 (0.79) | TBXAS1 | |
| SCHEMBL3172850 | 0.98 | TBXAS1 (0.79) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL3530240 | 0.96 | TBXAS1 (0.76) | TBXAS1 | |
| SCHEMBL78110 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912674-A | Cationic polyether macromonomer, preparation method thereof and concrete superplasticizer using cationic polyether macromonomer | 博特建材（天津）有限公司 | 2025-05-02 | — | — | CN | claimed |
| EP-4457258-A1 | POLYOL CATALYST FOR A TWO-COMPONENT POLYURETHANE SYSTEM | ARKEMA FRANCE (FR) | 2024-11-06 | — | — | EP | claimed |
| US-11897995-B2 | Allophanate based dispersing agent | BASF SE (DE) | 2024-02-13 | — | — | US | claimed |
| WO-2023126199-A1 | POLYOL CATALYST FOR A TWO-COMPONENT POLYURETHANE SYSTEM | ARKEMA FRANCE (FR) | 2023-07-06 | — | — | WO | claimed |
| US-20220275146-A1 | ALLOPHANATE BASED DISPERSING AGENT | BASF SE (DE) | 2022-09-01 | — | — | US | claimed |
| EP-3999570-A1 | ALLOPHANATE BASED DISPERSING AGENT | BASF SE (DE) | 2022-05-25 | — | — | EP | claimed |
| CN-114127150-A | Allophanate-based dispersants | 巴斯夫欧洲公司 | 2022-03-01 | — | — | CN | claimed |
| CN-110105332-A | A kind of preparation method for the adjustable compound ion liquid that shines | 山东大学 | 2019-08-09 | — | — | CN | claimed |
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | claimed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | claimed |
| CN-1886378-A | 1,4-disubstituted isoquinilone derivatives as RAF-kinase inhibitors useful for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2006-12-27 | — | — | CN | claimed |
| EP-1385828-A1 | COMPOUNDS OF THE FAMILY OF 3-ALKYL-(4,5 DIPHENY-IMIDAZOL-1-YL) AND THEIR USE AS SOOTHING AGENTS | L'OREAL (FR) | 2004-02-04 | — | — | EP | claimed |
| WO-2002085864-A1 | COMPOUNDS OF THE FAMILY OF 3-ALKYL-(4,5 DIPHENY-IMIDAZOL-1-YL) AND THEIR USE AS SOOTHING AGENTS | L'OREAL (FR) | 2002-10-31 | — | — | WO | claimed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | claimed |
| EP-0596802-B1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1996-03-20 | — | — | EP | claimed |
| EP-0596802-A1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1994-05-11 | — | — | EP | claimed |
| EP-0375451-A2 | Compounds having a renin-inhibiting activity | BEECHAM GROUP PLC (GB) | 1990-06-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | CDK2, SBK3, CDK2AP1 | TBXAS1 3167/4885HMOX1 4487/4885PRKCI 153/4885 |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | TBXAS1 1080/4885HMOX1 1912/4885PRKCI 68/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | TBXAS1 183/4885HMOX1 432/4885PRKCI 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.